Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Net Cash Flow: 2010-2025

Historic Net Cash Flow for Ani Pharmaceuticals (ANIP) over the last 15 years, with Sep 2025 value amounting to $44.2 million.

  • Ani Pharmaceuticals' Net Cash Flow rose 146.56% to $44.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $116.9 million, marking a year-over-year increase of 343.62%. This contributed to the annual value of -$75.8 million for FY2024, which is 145.12% down from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Net Cash Flow of $44.2 million as of Q3 2025, which was down 34.13% from $67.2 million recorded in Q2 2025.
  • Over the past 5 years, Ani Pharmaceuticals' Net Cash Flow peaked at $94.0 million during Q2 2023, and registered a low of -$95.0 million during Q3 2024.
  • Over the past 3 years, Ani Pharmaceuticals' median Net Cash Flow value was $14.5 million (recorded in 2023), while the average stood at $19.0 million.
  • As far as peak fluctuations go, Ani Pharmaceuticals' Net Cash Flow soared by 947.41% in 2021, and later tumbled by 1,567.69% in 2022.
  • Over the past 5 years, Ani Pharmaceuticals' Net Cash Flow (Quarterly) stood at $85.0 million in 2021, then crashed by 109.47% to -$8.1 million in 2022, then soared by 448.36% to $28.0 million in 2023, then plummeted by 99.03% to $272,000 in 2024, then surged by 146.56% to $44.2 million in 2025.
  • Its last three reported values are $44.2 million in Q3 2025, $67.2 million for Q2 2025, and $5.2 million during Q1 2025.